Claims for Patent: 9,695,241

Summary for Patent: 9,695,241

Title:	Ang2 antibodies
Abstract:	The present invention relates to antibodies that bind human angiopoietin-2 (Ang2), and may be useful for treating cancer alone and in combination with VEGF pathway inhibitors, especially cancer driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.
Inventor(s):	Leung; Donmienne Doen Mun (San Diego, CA), Xu; Jianghuai (San Diego, CA)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	14/709,514
Patent Claims:	1. An antibody that binds human Ang2 (SEQ ID NO: 7), comprising a light chain (LC) and a heavy chain (HC), wherein the light chain comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences KASQDVYIAVA (SEQ ID NO: 8), YWASTRDT (SEQ ID NO: 9), and HQYSSYPPT (SEQ ID NO: 10), respectively, and wherein the heavy chain comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3 consisting of the amino acid sequences GYSFTDYNMV (SEQ ID NO: 11), YIDPYNGGTGYNQKFEG (SEQ ID NO: 12), and ARTRDRYDVWYFDV (SEQ ID NO: 13), respectively. 2. An antibody, comprising a light chain (LC) and a heavy chain (HC), wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the LCVR has the amino acid sequence given in SEQ ID NO: 3, and the HCVR has the amino acid sequence given in SEQ ID NO: 1. 3. The antibody of claim 2, wherein the LC has the amino acid sequence given in SEQ ID NO: 4, and the HC has the amino acid sequence given in SEQ ID NO: 2. 4. The antibody of claim 3, comprising two light chains and two heavy chains, wherein each light chain has the amino acid sequence given in SEQ ID NO: 4, and each heavy chain has the amino acid sequence given in SEQ ID NO: 2. 5. The antibody of claim 4, wherein one of the heavy chains forms an inter-chain disulfide bond with one of the light chains, and the other heavy chain forms an inter-chain disulfide bond with the other light chain, and one of the heavy chains forms two inter-chain disulfide bonds with the other heavy chain. 6. The antibody of claim 5, wherein the antibody is glycosylated. 7. A mammalian cell comprising a DNA molecule comprising a polynucleotide sequence encoding a polypeptide having an amino acid sequence of SEQ ID NO: 4 and a polynucleotide sequence encoding a polypeptide having an amino acid sequence of SEQ ID NO: 2, wherein the cell is capable of expressing an antibody comprising a light chain having an amino acid sequence of SEQ ID NO: 4 and a heavy chain having an amino acid sequence of SEQ ID NO: 2. 8. A process for producing an antibody comprising a light chain having an amino acid sequence of SEQ ID NO: 4 and a heavy chain having an amino acid sequence of SEQ ID NO: 2, comprising cultivating the mammalian cell of claim 7 under conditions such that the antibody is expressed, and recovering the expressed antibody. 9. An antibody produced by the process of claim 8. 10. A pharmaceutical composition, comprising the antibody of any one of claim 1 or 2, and an acceptable carrier, diluent, or excipient. 11. A method of treating cancer, comprising administering to a patient in need thereof, an effective amount of the antibody of any one of claim 1 or 2. 12. The method of claim 11, wherein the cancer is breast cancer, ovarian cancer, gastric cancer, colorectal cancer, or hepatocellular carcinoma. 13. The method of claim 11, further comprising administering simultaneously, separately, or sequentially an effective amount of ramucirumab.

Details for Patent 9,695,241

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477	04/21/2014		2039-02-26